JNJ-7706621 is primarily utilized in research settings as a potent inhibitor of cyclin-dependent kinases (CDKs) and aurora kinases, which are critical enzymes involved in cell cycle regulation. Its application is significant in studying the mechanisms of cell division and proliferation, particularly in cancer research. By inhibiting these kinases, it helps researchers understand the pathways that drive uncontrolled cell growth, providing insights into potential therapeutic targets for cancer treatment. Additionally, it is used in preclinical studies to evaluate its efficacy in halting tumor progression and inducing apoptosis in cancer cells. This compound serves as a valuable tool for developing novel anticancer strategies and understanding the molecular basis of cell cycle dysregulation.